Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.3390/cancers12010113
Journal or Publication Title: Cancers
Volume: 12
Number: 1
Page Range: p. 113
Date: 2020
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.3390/cancers12010113
ISSN: 2072-6694
Date Deposited: 04 Jan 2021 00:18
Abstract:

Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

Creators:
Creators
Email
A. A. Aljabali, Alaa
UNSPECIFIED
A. Bakshi, Hamid
UNSPECIFIED
L. Hakkim, Faruck
UNSPECIFIED
Haggag, Yusuf A.
UNSPECIFIED
M. Al-Batanyeh, Khalid
UNSPECIFIED
S. Al Zoubi, Mazhar
UNSPECIFIED
Al-Trad, Bahaa
UNSPECIFIED
M. Nasef, Mohamed
UNSPECIFIED
Satija, Saurabh
UNSPECIFIED
Mehta, Meenu
UNSPECIFIED
Pabreja, Kavita
UNSPECIFIED
Mishra, Vijay
UNSPECIFIED
Khan, Mohammed
UNSPECIFIED
Abobaker, Salem
UNSPECIFIED
M. Azzouz, Ibrahim
UNSPECIFIED
Dureja, Harish
UNSPECIFIED
M. Pabari, Ritesh
UNSPECIFIED
Ali K. Dardouri, Ashref
UNSPECIFIED
Kesharwani, Prashant
UNSPECIFIED
Gupta, Gaurav
UNSPECIFIED
Dhar Shukla, Shakti
UNSPECIFIED
Prasher, Parteek
UNSPECIFIED
B. Charbe, Nitin
UNSPECIFIED
Negi, Poonam
UNSPECIFIED
N. Kapoor, Deepak
UNSPECIFIED
Chellappan, Dinesh Kumar
UNSPECIFIED
Webba da Silva, Mateus
UNSPECIFIED
Thompson, Paul
UNSPECIFIED
Dua, Kamal
UNSPECIFIED
McCarron, Paul
UNSPECIFIED
M. Tambuwala, Murtaza
UNSPECIFIED
Last Modified: 04 Jan 2021 00:18
URI: https://eprints.centenary.org.au/id/eprint/816

Actions (login required)

View Item View Item